<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099341</url>
  </required_header>
  <id_info>
    <org_study_id>CHAUVET CRBFC-E 2019</org_study_id>
    <nct_id>NCT05099341</nct_id>
  </id_info>
  <brief_title>DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls</brief_title>
  <acronym>DepLIPIDO</acronym>
  <official_title>DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is a disabling condition in terms of psychosocial alteration and also in terms of&#xD;
      physical comorbidities. Depression doubles the risk of myocardial infarction compared with&#xD;
      the general population, and this cardiovascular comorbidity leads to an increase in mortality&#xD;
      in patients suffering from depression, even exceeding suicide-related mortality.&#xD;
&#xD;
      It is therefore important to better understand the mechanisms linking depression and&#xD;
      cardiovascular disease.&#xD;
&#xD;
      Among the hypotheses that may account for the increased cardiovascular risk in patients with&#xD;
      depression, lipid abnormalities are likely to play a crucial role.&#xD;
&#xD;
      Thus, qualitative and functional abnormalities in HDL lipoproteins are an important line of&#xD;
      research, insofar as these lipid abnormalities have been recognized as important atherogenic&#xD;
      abnormalities in populations at high cardiovascular risk, which is the case of patients with&#xD;
      depression.&#xD;
&#xD;
      In this clinical, epidemiological and scientific context, a collaborative study undertaken by&#xD;
      both the Department of Psychiatry of the Dijon Bourgogne University Hospital of and the&#xD;
      INSERM LNC-UMR 1231 (PADYS) Laboratory of the UNIVERSITY OF BOURGOGNE FRANCHE-COMTE is an&#xD;
      original translational research project, and the first study to perform a lipidomic analysis&#xD;
      of HDL, coupled with a functional analysis of these lipoproteins in depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of cholesterol efflux by fluorescent method on THP-1 cell derived macrophages</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Patients with recurrent depression with a number of depressive episodes ≥ 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with a first depressive episode</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy, non-depressed subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HDRS-17 depression scale</intervention_name>
    <description>Measuring the severity of depression</description>
    <arm_group_label>Healthy, non-depressed subjects</arm_group_label>
    <arm_group_label>Patients with a first depressive episode</arm_group_label>
    <arm_group_label>Patients with recurrent depression with a number of depressive episodes ≥ 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>3 tubes of 5 ml</description>
    <arm_group_label>Healthy, non-depressed subjects</arm_group_label>
    <arm_group_label>Patients with a first depressive episode</arm_group_label>
    <arm_group_label>Patients with recurrent depression with a number of depressive episodes ≥ 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FOR PATIENTS WITH RECURRENT DEPRESSION :&#xD;
&#xD;
               -  Patient who has provided oral consent&#xD;
&#xD;
               -  Adult with moderate to severe depression according to DSM-5 criteria (Hamilton&#xD;
                  HDRS-17 score ≥ 18), with a number of depressive episodes ≥ 3&#xD;
&#xD;
          -  PATIENTS PRESENTING WITH A FIRST DEPRESSIVE EPISODE&#xD;
&#xD;
               -  Patient who has provided oral consent&#xD;
&#xD;
               -  Adult with moderate to severe characterized depression according to DSM-5&#xD;
                  criteria (Hamilton HDRS-17 scale score ≥ 18) presenting with a first depressive&#xD;
                  episode.&#xD;
&#xD;
          -  CONTROLS&#xD;
&#xD;
               -  Person who has provided oral consent&#xD;
&#xD;
               -  Adult who has never shown signs of depression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person not affiliated with national health insurance&#xD;
&#xD;
          -  Person subject to a measure of legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Adult unable to express consent&#xD;
&#xD;
          -  Minors&#xD;
&#xD;
          -  Person with a metabolic syndrome (according to NCEP/ATP-III criteria: 3 of the&#xD;
             following 5 criteria: Waist circumference ≥ 102 cm in males and ≥ 88cm in females,&#xD;
             Triglycerides &gt; 1.50 g/L, HDL-Cholesterol &lt; 0.40 g/L in H, HDL-Cholesterol &lt; 0.50 g/L&#xD;
             in F, Blood pressure ≥130/85mmHg, Fasting blood glucose ≥ 1.10 g/L),&#xD;
&#xD;
          -  Person with type 1 or type 2 diabetes,&#xD;
&#xD;
          -  Person with a mild depressive episode (HDRS-17&lt;18),&#xD;
&#xD;
          -  Person with concomitant antipsychotic treatment&#xD;
&#xD;
          -  Person with bipolar disorder,&#xD;
&#xD;
          -  Person with a moderate to severe alcohol use disorder according to DSM-5 criteria&#xD;
&#xD;
          -  Person with schizophrenia,&#xD;
&#xD;
          -  Person with a persistent delusional disorder,&#xD;
&#xD;
          -  Person with an autism spectrum disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe CHAUVET-GELINIER</last_name>
    <phone>03 80 29 37 69</phone>
    <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe CHAUVET-GELINIER</last_name>
      <phone>03 80 29 37 69</phone>
      <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

